AI
ATRS

Atria Investments’s Antares Pharma, Inc. ATRS Stock Holding History

Atria Investments’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-15,098
Closed -$25K – 692
2016
Q3 		$25K Sell
15,098
-379
-2% -$464 ﹤0.01% 543
2016
Q2 		$15K Buy
15,477
+2,669
+21% +$2.58K ﹤0.01% 467
2016
Q1 		$11K Buy
+12,808
New +$12.4K ﹤0.01% 439

Other funds holding ATRS

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Atria Investments's ATRS Position: Q4 2016 in Review

Atria Investments sold out of Antares Pharma, Inc. (ATRS) in Q4 2016, closing a stake of 15,098 shares — an estimated $25K sold.

Atria Investments first reported a position in ATRS in Q1 2016 and held it in 3 quarters. The position peaked at $25K in Q3 2016. 71 funds tracked by Wall St. Rank hold ATRS as of Q4 2016.

  • Atria Investments reported no remaining Antares Pharma, Inc. position as of Q4 2016 after selling out during the quarter.
  • Atria Investments sold 15,098 Antares Pharma, Inc. shares in Q4 2016, an estimated $25K.
  • Atria Investments first reported a position in Antares Pharma, Inc. in Q1 2016 and held it in 3 quarters.
  • Atria Investments's Antares Pharma, Inc. position peaked at $25K in Q3 2016.
  • 71 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2016.

Based on Atria Investments's 13F filing for Q4 2016, filed 13 Jan 2017.